前列腺癌关键基因诊疗策略的前沿进展

Prostate cancer, as one of the common malignant tumors in men, has increasingly become a significant male health issue that severely affects the health and quality of life of patients worldwide. The early and precise diagnosis and treatment of prostate cancer are currently key areas that require attention. Prostate-specific antigen testing, imaging examinations, and biopsy are widely used in clinical settings, and the application of the second-generation prostate cancer-related gene screening is also becoming more prevalent. There is a multitude of genes associated with prostate cancer. This article provides an overview of common genes in prostate cancer genetic testing, such as Homologous Recombination Repair (HRR) genes and their representatives, Breast Cancer susceptibility gene 1/2 (BRCA1/2), Tumor Protein P53 (TP53) gene, Homeobox B13 (HOXB13) gene, and Phosphatase and Tensin Homolog (PTEN) gene. Furthermore, the article discusses the cutting-edge research and hot topics in the diagnosis and targeted therapy of prostate cancer involving the aforementioned genes, both domestically and internationally.